Disease · MONDO_0020561
myxoid/round cell liposarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. myxoid/round cell liposarcoma. Diseases, record MONDO_0020561. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020561
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LETETRESGENE AUTOLEUCEL | CHEMBL4650238 | Gene | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INTERFERON GAMMA-1B | CHEMBL1201564 | Protein | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NOGAPENDEKIN ALFA INBAKICEPT | CHEMBL6068330 | Protein | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IFNGR1 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3459 | Drugs and targets |
| IFNGR2 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3460 | Drugs and targets |
| IL15RA | Interleukin-15 receptor | 1 | Interleukin-15 receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3601 | Drugs and targets |
| IL2RB | Interleukin-15 receptor | 1 | Interleukin-15 receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-15 receptor | 1 | Interleukin-15 receptor agonist | Early phase 1 | https://conductscience.org/library/genes/3561 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 1 | Programmed cell death protein 1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| POLA1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1 | https://conductscience.org/library/genes/5422 | Drugs and targets |
| POLA2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1 | https://conductscience.org/library/genes/23649 | Drugs and targets |
| POLD1 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1 | https://conductscience.org/library/genes/5424 | Drugs and targets |
| POLD2 | DNA polymerase (alpha/delta/epsilon) | 1 | DNA polymerase (alpha/delta/epsilon) inhibitor | Phase 1 | https://conductscience.org/library/genes/5425 | Drugs and targets |
1 to 10 of 20
See all 20 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02992743 | Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma | Phase 2 | 23 | 2022-11-28 | Neoplasms | CYCLOPHOSPHAMIDE, FLUDARABINE, LETETRESGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Phase 1/2 | 16 | 2024-08-06 | Ovarian Cancer, NSCLC, ESCC, Solid Tumors | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | Early phase 1 | 8 | 2019-07-10 | Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma | INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT05993299 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | Phase 2 | 7 | 2023-10-16 | Neoplasms | LETETRESGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT03967223 | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | Phase 2 | 103 | Neoplasms | CYCLOPHOSPHAMIDE, FLUDARABINE, LETETRESGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT06703346 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Phase 2 | 82 | Neoplasms | LETETRESGENE AUTOLEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT06083883 | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | Phase 1 | 44 | Synovial Sarcoma, Myxoid/Round Cell Liposarcoma | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | Its record names the disease | ClinicalTrials.gov | |
| NCT07261657 | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy | Early phase 1 | 8 | Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma | NOGAPENDEKIN ALFA INBAKICEPT | Its record names the disease | ClinicalTrials.gov | |
| NCT01477021 | Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery | Phase 1 | 6 | Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | Phase 1 | 0 | Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | CYCLOPHOSPHAMIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: deaths from any cause | 5 of 13 | 0 of 10 | 23 | NCT02992743 | Trial comparisons |
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: serious adverse events | 5 of 13 | 7 of 10 | 23 | NCT02992743 | Trial comparisons |
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: Number of Participants With Replication Competent Lentivirus (RCL) | 0 of 10 | 0 of 8 | 18 | NCT02992743 | Trial comparisons |
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: Number of Participants With Positive Anti-drug Antibodies (ADAs) | 0 of 7 | 0 of 10 | 17 | NCT02992743 | Trial comparisons |
| Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: Number of Participants With Insertional Oncogenesis | 0 of 1 | 0 of 2 | 3 | NCT02992743 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020561
GET https://conductscience.org/api/diseases/v1/MONDO_0020561/drugs